The effect of inhaled nitric oxide on shunt fraction in mechanically ventilated patients with COVID-19 pneumonia.
Acute respiratory dieases syndrome
COVID-19
inhaled nitric oxide
Journal
African journal of thoracic and critical care medicine
ISSN: 2617-0205
Titre abrégé: Afr J Thorac Crit Care Med
Pays: South Africa
ID NLM: 101751995
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
08
2022
accepted:
03
05
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
Studies in patients with severe acute respiratory distress syndrome (ARDS) with refractory hypoxaemia suggest that inhaled nitric oxide (iNO) can be added to ventilatory strategies as a potential bridge to clinical improvement. However, the potential role of iNO as a management strategy in severe COVID-19 pneumonia remains unclear. The authors describe their clinical findings of using iNO for severe COVID-19 pneumonia in 10 patients with refractory hypoxaemia in a tertiary respiratory intensive care unit. The results showed an improvement in shunt fraction, P/F ratio, PaO This brief report adds to the body of literature exploring the potential use of inhaled nitric oxide as a management strategy in patients with severe COVID-19 pneumonia with refractory hypoxaemia. The findings of the report shows that there is a beneficial role of using inhaled nitric oxide to improve respiratory parameters, but that it does not translate to a mortality benefit. It adds to the investigation of establishing which patients, the duration and at what dose, inhaled nitric oxide should be used to gain maximum benefit for this subgroup of patients.
Sections du résumé
Background
UNASSIGNED
Studies in patients with severe acute respiratory distress syndrome (ARDS) with refractory hypoxaemia suggest that inhaled nitric oxide (iNO) can be added to ventilatory strategies as a potential bridge to clinical improvement. However, the potential role of iNO as a management strategy in severe COVID-19 pneumonia remains unclear. The authors describe their clinical findings of using iNO for severe COVID-19 pneumonia in 10 patients with refractory hypoxaemia in a tertiary respiratory intensive care unit. The results showed an improvement in shunt fraction, P/F ratio, PaO
What the study adds
UNASSIGNED
This brief report adds to the body of literature exploring the potential use of inhaled nitric oxide as a management strategy in patients with severe COVID-19 pneumonia with refractory hypoxaemia.
What are the implications of the findings
UNASSIGNED
The findings of the report shows that there is a beneficial role of using inhaled nitric oxide to improve respiratory parameters, but that it does not translate to a mortality benefit. It adds to the investigation of establishing which patients, the duration and at what dose, inhaled nitric oxide should be used to gain maximum benefit for this subgroup of patients.
Identifiants
pubmed: 37622104
doi: 10.7196/AJTCCM.2023.v29i2.279
pmc: PMC10446161
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright © 2022, van Zyl et al. Copyright of published material remains in the Authors’ name. This allows authors to use their work for their own non-commercial purposes without seeking permission from the Publisher, subject to properly acknowledging the Journal as the original place of publication.
Déclaration de conflit d'intérêts
Conflicts of interest: None.
Références
Acta Anaesthesiol Scand. 2021 May;65(5):629-632
pubmed: 33296498
Cochrane Database Syst Rev. 2016 Jun 27;(6):CD002787
pubmed: 27347773
Acta Anaesthesiol Scand. 2021 Nov;65(10):1522-1523
pubmed: 34309854
Anesthesiology. 1997 Aug;87(2):297-307
pubmed: 9286894
J Crit Care. 2020 Dec;60:159-160
pubmed: 32814271
S Afr Med J. 2020 Apr 23;110(6):463-465
pubmed: 32880553
Biomedicines. 2022 Feb 03;10(2):
pubmed: 35203578
Turk J Anaesthesiol Reanim. 2020 Feb;48(1):2-10
pubmed: 32076673
BMJ Open Respir Res. 2019 May 24;6(1):e000420
pubmed: 31258917
Am J Respir Crit Care Med. 2011 Sep 1;184(5):514-20
pubmed: 21177882
Cureus. 2022 Apr 5;14(4):e23852
pubmed: 35530860